| Titre : | A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence |
| Titre traduit : | (Essai thérapeutique placebo contrôlé de olanzapine, valproate, and coenzyme Q10/L-carnitine pour le traitement de la dépendance à la cocaïne) |
| Auteurs : | M. S. REID ; P. CASADONTE ; S. BAKER ; SANFILIPO M. ; BRAUNSTEIN D. ; HITZEMANN A. ; A. MONTGOMERY ; M. D. MAJEWSKA ; J. ROBINSON ; J. ROTROSEN |
| Type de document : | Périodique |
| Année de publication : | 2005 |
| Format : | 43-57 / graph. ; tabl. |
| Note générale : |
Addiction, 2005, 100, (Suppl. 1 Clinical Rapid Eficacy Screening Trials (CREST)), 43-57 |
| Langues: | Anglais |
| Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
| Mots-clés : |
Thésaurus mots-clés COCAINE ; DEPENDANCE ; PHARMACOTHERAPIE ; MEDICAMENTS ; ESSAI THERAPEUTIQUE ; PLACEBO |
| Résumé : |
ENGLISH : Aims : To conduct a medication screening trial on the efficacy of olanzapine, valproate or coenzyme Q10/L-carnitine combination versus placebo for the treatment of cocaine dependence. Design : A four-arm, modified blinded, parallel group study in an out-patient setting using the Cocaine Rapid Efficacy and Safety Trials (CREST) study design. Setting : The study was performed at the New York Medications Development Research Unit (MDRU). Participants : All participants met Diagnostic and Statistical Manual version IV (DSM-IV) criteria for cocaine dependence and provided at least two urine samples positive for benzoylecgonine (BE) during the 2-week screening period. Sixty-eight participants were enrolled with 39 completing the study. Intervention : After a 2-week screening period, 68 subjects were assigned randomly to receive either olanzapine (10 mg/day), valproate (1500 mg/day), coenzyme Q10 (200 mg/day) and L-carnitine (500 mg/day) combination or placebo for an 8-week treatment period. All subjects also received individual cognitive behavioral counseling during treatment. Measurements : Primary outcome measures included quantitative urine benzoylecgonine (BE) levels, self-report of drug use, and global impression scores. Secondary outcomes included cocaine craving, study retention and related psychosocial measures. Safety measures included adverse event monitoring, vital signs, and extrapyramidal side-effects tests. Results : Study retention was similar across all treatment groups, and all groups showed improvement across most measures of treatment efficacy over the duration of the study. None of the study medications, however, were superior to placebo on any of the primary or secondary outcome measures. Cocaine use, as measured by urine BE levels and self-report, was not significantly lower than placebo in any of the drug treatment groups. All study medications were equally well tolerated, and few medication side effects were observed. Conclusion : This pilot study does not support the effectiveness of olanzapine, valproate or coenzyme Q10/ L-carnitine combination for the treatment of cocaine dependence. (Review' s abstract) |
| Note de contenu : | graph. ; tabl. |
| Domaine : | Drogues illicites / Illicit drugs |
| Sous-type de document : | N° spécial de revue / Special issue of a journal |
| Refs biblio. : | 61 |
| Affiliation : |
Department of Psychiatry New York University School of Medicine VA NYHHS 116 A, 423 E. 23rd Street New York NY 10010 ; malcolm.reid@med.va.gov Etats-Unis. United States. |
| Numéro Toxibase : | 208107 |
| Centre Emetteur : | 02 Coordonnateur |
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |
Accueil
